Soligenix to Present at BIO Investment & Growth Summit
Rhea-AI Summary
Soligenix (Nasdaq: SNGX) announced that Christopher J. Schaber, Ph.D., President & CEO, will deliver a corporate presentation at the BIO Investment & Growth Summit on Monday, March 2 at 3:00 PM in Miami Beach, Florida.
Registered attendees may schedule one-on-one meetings via the conference platform; non-attendees can request meetings by emailing ir@soligenix.com. The summit runs March 2–3 at Eden Roc Miami Beach.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Scanner data shows no coordinated sector move. Peers are mixed, with moves from +238.84% (LPTX) and modest gains in MBIO and XTLB, while MBRX and SNSE show declines. With SNGX flat at 0%, trading appears stock-specific rather than driven by a broad biotechnology rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Pipeline and cash update | Positive | -1.9% | Detailed FLASH2 Phase 3 timing and cash position with reiterated commercial estimates. |
| Dec 18 | Phase 2 data SGX945 | Positive | +0.0% | Publication of positive Phase 2a Behçet’s Disease results showing durable treatment benefit. |
| Dec 17 | SGX302 psoriasis topline | Positive | -19.1% | Top-line Phase 2a extension data with clinical improvements and good tolerability. |
| Dec 05 | Rare-disease editorial | Positive | -2.4% | Editorial highlighting Soligenix’s rare-disease focus and HyBryte’s late-stage status. |
| Dec 03 | CTCL platform editorial | Positive | -1.9% | Editorial on HyBryte as a novel CTCL therapy and company’s late‑stage positioning. |
Recent history shows largely positive clinical and pipeline news often followed by flat or negative price reactions, suggesting a pattern of market skepticism or limited response to updates.
Over the past few months, Soligenix has highlighted progress across multiple rare-disease programs. Updates included HyBryte’s confirmatory Phase 3 FLASH2 timeline, positive Phase 2 data for SGX945 in Behçet’s Disease, and encouraging SGX302 psoriasis results, alongside editorial coverage emphasizing its late-stage status. Despite these generally constructive developments between Dec 3, 2025 and Feb 12, 2026, share reactions were often negative or flat, indicating a disconnect between news flow and market response.
Market Pulse Summary
This announcement highlights Soligenix’s participation in the BIO Investment & Growth Summit, offering management an additional venue to communicate its late-stage rare-disease pipeline and strategy. In recent months, the company detailed HyBryte’s confirmatory Phase 3 plans, positive SGX302 and SGX945 data, and capital position through 2026. Investors may watch for new partnership discussions, updates tied to these programs, and any follow-on communications emerging from meetings around the conference.
AI-generated analysis. Not financial advice.
Registered conference attendees may schedule a meeting with Soligenix via the conference scheduling platforms. If you are unable to attend the conferences and would like to schedule a meeting with management, please contact ir@soligenix.com.
About Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behçet's Disease.
Our Public Health Solutions business segment includes development programs for RiVax®, our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).
For further information regarding Soligenix, Inc., please visit the Company's website at https://www.soligenix.com and follow us on LinkedIn and Twitter at @Soligenix_Inc.
This press release may contain forward-looking statements that reflect Soligenix's current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations, clinical trial enrollment. Statements that are not historical facts, such as "anticipates," "estimates," "believes," "hopes," "intends," "plans," "expects," "goal," "may," "suggest," "will," "potential," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/soligenix-to-present-at-bio-investment--growth-summit-302695396.html
SOURCE SOLIGENIX, INC.
FAQ
When is Soligenix (SNGX) presenting at the BIO Investment & Growth Summit in 2026?
Where is the BIO Investment & Growth Summit taking place for Soligenix's (SNGX) presentation?
How can investors schedule a meeting with Soligenix (SNGX) at the March 2026 BIO summit?
Who will present for Soligenix (SNGX) at the BIO Investment & Growth Summit on March 2, 2026?
Will Soligenix (SNGX) offer one-on-one investor meetings at the March 2–3, 2026 summit?
Where can I find more information about the BIO Investment & Growth Summit where Soligenix (SNGX) will present?
